This includes the expansion of its CardioCel® regenerative tissue repair product for repairing and reconstructing heart defects as well as results from the Phase 1 clinical trial of its herpes therapeutic vaccine.
CardioCel has recently received its first European sale and is awaiting approval for marketing to begin in the U.S.
Meanwhile, the Phase 1 trial looks set to achieve its key objective, which is to determine the safety of the vaccine. Interim results are anticipated towards the end of 2013 / early 2014 with full results in mid-2014.
All other corporate details, including the company's ASX code, remain unchanged.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.